BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
- End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) scheduled for June of 2022; Plan to initiate the Phase 3 program in the second half of 2022 - - Three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTH